STAT3 Signaling in Oral Squamous Cell Carcinoma: Mechanisms, Tumor Microenvironment, Therapy Resistance, and Therapeutic Targeting
Year: 2026
Type: article
Abstract: Oral squamous cell carcinoma (OSCC) remains a major clinical challenge because of late diagnosis, frequent recurrence, metastatic spread, and resistance to chemotherapy and radiotherapy. Signal transducer and activator of transcription 3 (STAT3) is a central signaling hub that integrates cytokine-, growth factor-, metabolic-, and stress-derived inputs in both malignant cells and the tumor microenvironment. This review summarizes canonical and non-canonical STAT3 activation and examines its contribution to OSCC initiation and progression. Persistent STAT3 signaling promotes proliferation, survival, epithelial–mesenchymal plasticity, invasion, angiogenesis, cancer stemness, metabolic adaptation, immune evasion, and resistance to treatment. Its activity is sustained by IL-6/JAK signaling, receptor and non-receptor tyrosine kinases, loss of negative regulators, non-coding RNAs, and reciprocal interactions with fibroblasts, macrophages, neutrophils, mesenchymal stromal cells, and suppressive myeloid populations. Therapeutic approaches include IL-6/JAK blockade, direct or proximal STAT3 inhibitors, decoy oligonucleotides, natural and repurposed compounds, and combinations with chemotherapy, radiotherapy, or immune-checkpoint inhibition. Although preclinical evidence is substantial, clinical translation remains limited by pathway heterogeneity, incomplete drug selectivity, systemic toxicity, and the absence of validated predictive biomarkers. Biomarker-guided trials and pharmacodynamically verified combination strategies are therefore required to establish STAT3 as a clinically actionable target in OSCC.
Source: Medical Sciences
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: oral squamous cell carcinoma, STAT3 signaling, tumor microenvironment, treatment resistance, cancer stemness, epithelial-mesenchymal plasticity, tumor immune evasion, STAT3 inhibitor, decoy oligonucleotides, drug repurposing, combination therapy, predictive biomarkers, macrophage-fibroblast interaction, cancer metabolism
Open Access status: gold
Estimated APC paid: $1,689
OpenAlex ID: W7235141082
